Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia

@article{Wstenberg2011RecombinantHE,
  title={Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia},
  author={Torsten W{\"u}stenberg and Martin Begemann and Claudia Bartels and Olaf Gefeller and Sabina Stawicki and Dunja Hinze-Selch and A. Mohr and Peter Falkai and Joseph B Aldenhoff and Michael Knauth and K-A Nave and Hannelore Ehrenreich},
  journal={Molecular Psychiatry},
  year={2011},
  volume={16},
  pages={26-36}
}
Neurodevelopmental abnormalities together with neurodegenerative processes contribute to schizophrenia, an etiologically heterogeneous, complex disease phenotype that has been difficult to model in animals. The neurodegenerative component of schizophrenia is best documented by magnetic resonance imaging (MRI), demonstrating progressive cortical gray matter loss over time. No treatment exists to counteract this slowly proceeding atrophy. The hematopoietic growth factor erythropoietin (EPO) is… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Neuroprotective effects of erythropoietin on Alzheimer's dementia model in rats.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University • 2017

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Amygdala volume and verbal memory performance in schizophrenia and bipolar disorder.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology • 2009

FMRI indices of auditory attention in schizophrenia.

Progress in neuro-psychopharmacology & biological psychiatry • 2009

Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system

AL Sirén, T Fasshauer, C Bartels, H Ehrenreich
Neurotherapeutics • 2009

Similar Papers

Loading similar papers…